Caris Life Sciences, Inc. Stock: price and insider trades · United States

Caris Life Sciences, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for Caris Life Sciences, Inc. logged 46 filings by 20 insiders.

Purchases and sales both appear in the filings: 3 purchases (3 insiders, €947k) and 7 sales (4 insiders, €25.0M). Netting one side against the other leaves €24.0M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €10.6M, sold by Brille Brian J and made public on 17 September 2026. On the buying side, the filings list 1 senior executive and 1 chief executive among the declarants.

Across the 5,462 companies tracked on its exchange, the median is 28 filings; at 46 filings, this issuer sits above that mark. The full history, which starts in 2025, counts 5 purchases against 7 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 812.0 m USD and net income at -68.1 m USD.

The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last purchase on record was published on 13 July 2026, which is 102 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

In the same market, recent insider purchases at GameStop Corp. and Xenon Pharmaceuticals Inc. also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.